Organ allocation in the United States: where does it stand? Point.

PubWeight™: 1.38‹?› | Rank: Top 10%

🔗 View Article (PMID 11192911)

Published in J Am Coll Surg on January 01, 2001


J J Fung

Articles citing this

Organ allocation in the United States: where does it stand? Counterpoint. J Am Coll Surg (2001) 0.75

Articles by these authors

(truncated to the top 100)

Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76

The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89

Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01

Intestinal transplantation in composite visceral grafts or alone. Ann Surg (1992) 4.96

Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32

Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18

Liver transplantation in the United States, 1999-2008. Am J Transplant (2010) 3.92

Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63

Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40

Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34

Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29

Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26

Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18

The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14

Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg (2000) 2.91

Functional characterization of infiltrating T lymphocytes in human hepatic allografts. Hum Immunol (1986) 2.84

Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. Transplant Proc (1993) 2.81

Cadaveric small bowel and small bowel-liver transplantation in humans. Transplantation (1992) 2.75

Management of intestinal transplantation in humans. Transplant Proc (1992) 2.62

Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc (1990) 2.60

Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation (1990) 2.59

Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc (1991) 2.59

The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. Hepatology (1997) 2.57

FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation (1994) 2.50

Pregnancy after liver transplantation under tacrolimus. Transplantation (1997) 2.50

Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc (1990) 2.48

Prioritization and organ distribution for liver transplantation. JAMA (1994) 2.38

The antibody crossmatch in liver transplantation. Surgery (1986) 2.33

The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. Ann Surg (1994) 2.32

Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg (1998) 2.31

Differential survival of hamster-to-rat liver and cardiac xenografts under FK 506 immunosuppression. Transplant Proc (1991) 2.28

Assessment of five-year experience with abdominal organ cluster transplantation. J Am Coll Surg (1995) 2.25

Should HLA mismatch acceptability for sensitized transplant candidates be determined at the high-resolution rather than the antigen level? Am J Transplant (2015) 2.24

Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg (1999) 2.22

Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant (2006) 2.22

Three years clinical experience with intestinal transplantation. J Am Coll Surg (1994) 2.20

Human islet isolation and allotransplantation in 22 consecutive cases. Transplantation (1992) 2.20

Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology (1999) 2.19

Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg (1997) 2.16

Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis (1996) 2.12

One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. Transplant Proc (1991) 2.10

A prospective randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation (1995) 2.09

The side effects of FK 506 in humans. Transplant Proc (1990) 2.08

Randomised trialomania? The multicentre liver transplant trials of tacrolimus. Lancet (1995) 2.04

Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg (1998) 1.99

Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. Transplantation (1991) 1.95

FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood. Lancet (1990) 1.94

Successful hamster-to-rat liver xenotransplantation under FK506 immunosuppression induces unresponsiveness to hamster heart and skin. Transplantation (1993) 1.94

Acute liver failure: clinical features, outcome analysis, and applicability of prognostic criteria. Liver Transpl (2000) 1.88

Growth of donor-derived dendritic cells from the bone marrow of murine liver allograft recipients in response to granulocyte/macrophage colony-stimulating factor. J Exp Med (1995) 1.88

Costimulatory molecule-deficient dendritic cell progenitors (MHC class II+, CD80dim, CD86-) prolong cardiac allograft survival in nonimmunosuppressed recipients. Transplantation (1996) 1.86

Experience with liver and kidney allografts from non-heart-beating donors. Transplantation (1995) 1.83

Orthotopic liver transplantation in the mouse. Transplantation (1991) 1.82

Apoptosis within spontaneously accepted mouse liver allografts: evidence for deletion of cytotoxic T cells and implications for tolerance induction. J Immunol (1997) 1.81

Pathologic observations in human allograft recipients treated with FK 506. Transplant Proc (1990) 1.80

Early events in liver allograft rejection. Delineation of sites of simultaneous intragraft and recipient lymphoid tissue sensitization. Am J Pathol (1991) 1.78

Use of FK 506 in pediatric patients. Transplant Proc (1991) 1.77

Randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone after renal transplantation: preliminary report. Transplant Proc (1993) 1.72

Transplantation. JAMA (1990) 1.71

Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation (1999) 1.70

Interactions between bronchoalveolar lymphocytes and macrophages in heart-lung transplant recipients. Hum Immunol (1985) 1.65

Histocompatibility and liver transplant outcome. Does HLA exert a dualistic effect? Transplantation (1988) 1.61

Incidence and risk factors associated with the development of cytomegalovirus disease after intestinal transplantation. Transplantation (1995) 1.59

Weaning of immunosuppression in long-term liver transplant recipients. Transplantation (1995) 1.59

The spectrum of portal vein thrombosis in liver transplantation. Ann Surg (1991) 1.58

De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial. Am J Transplant (2014) 1.57

Weaning of immunosuppression in liver transplant recipients. Transplantation (1997) 1.57

Oral glucose tolerance test in liver recipients treated with FK 506. Transplant Proc (1990) 1.56

Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity? Am J Surg Pathol (2000) 1.56

Liver transplantation for Wilson's disease: a single-center experience. Liver Transpl Surg (1999) 1.55

Piggyback orthotopic intestinal transplantation. Surg Gynecol Obstet (1993) 1.55

Immunomodulation for intestinal transplantation by allograft irradiation, adjunct donor bone marrow infusion, or both. Transplantation (2000) 1.53

Split tolerance induced by orthotopic liver transplantation in mice. Transplantation (1994) 1.52

A clinicopathological study of human liver allograft recipients harboring preformed IgG lymphocytotoxic antibodies. Hepatology (1992) 1.50

Human biliary epithelial cells secrete and respond to cytokines and hepatocyte growth factors in vitro: interleukin-6, hepatocyte growth factor and epidermal growth factor promote DNA synthesis in vitro. Hepatology (1994) 1.49

FK 506 reverses acute graft-versus-host disease after allogeneic bone marrow transplantation in rats. Surgery (1991) 1.49

An analysis of early renal transplant protocol biopsies--the high incidence of subclinical tubulitis. Am J Transplant (2001) 1.48

Pancreas transplantation with enteric drainage under tacrolimus induction therapy. Transplant Proc (1997) 1.48

Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy--a clinicopathologic study of 96 patients. Transplantation (1992) 1.45

The influence of hepatitis C virus genotypes on the outcome of liver transplantation. Liver Transpl Surg (1998) 1.42

Analysis of chronic rejection and obliterative arteriopathy. Possible contributions of donor antigen-presenting cells and lymphatic disruption. Am J Pathol (1997) 1.41

Venous-right atrial bypass for superior vena cava thrombosis during orthotopic liver transplantation. Transplantation (1997) 1.39

Hepatic resection and transplantation for peripheral cholangiocarcinoma. J Am Coll Surg (1997) 1.36

Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation. Hepatology (1997) 1.36

Immunological quantitation and localization of ACAT-1 and ACAT-2 in human liver and small intestine. J Biol Chem (2000) 1.36

Impact of Orthoclone OKT3 on liver transplantation. Transplant Proc (1987) 1.36

OKT3 in the reversal of acute hepatic allograft rejection. Transplant Proc (1987) 1.35

Neurologic complications of FK 506. Transplant Proc (1991) 1.34

Liver transplantation for hepatocellular carcinoma: a proposal of a prognostic scoring system. J Am Coll Surg (2000) 1.33

Single-center experience with primary orthotopic liver transplantation with FK 506 immunosuppression. Ann Surg (1994) 1.33

Assay of FK 506 in plasma. Transplant Proc (1990) 1.32

Tacrolimus (FK 506)--a new therapeutic agent for severe recalcitrant psoriasis. Arch Dermatol (1992) 1.32

The development and compensation of biliary cirrhosis in interleukin-6-deficient mice. Am J Pathol (2000) 1.31

Effect of donor age and sex on the outcome of liver transplantation. Hepatology (1995) 1.31

Infections with FK 506 immunosuppression: preliminary results with primary therapy. Transplant Proc (1990) 1.30

Management of splenic artery aneurysms: the significance of portal and essential hypertension. J Am Coll Surg (1999) 1.28

Current status of intestinal transplantation in children. J Pediatr Surg (1998) 1.28

Liver transplantation with cavoportal hemitransposition in the presence of diffuse portal vein thrombosis. Transplantation (1998) 1.28

Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. Transplantation (1998) 1.28

Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am J Transplant (2006) 1.26